% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

  • nomenome91 nomenome91 Dec 20, 2013 2:09 PM Flag

    updates on clincal trials dot gov

    There are several updated trials. The H&N had its completion date moved back to Sept 2014. This is exactly like the result seen for the PII head and neck where the last patient went out two years. What I don't under stand is what they mean by the primary measures completion occurring in June of 2014. Do they not think they will be able to unblind until then? BT did say that they expect to unblind in H1 of 2014. Maybe they are being conservative. Time will tell.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • nome - thanks - thats interesting. Can I ask an ignorant question. Does completion date normally mean the date beyond which the trial formally ends ie. the company stops monitoring/treating/paying hospitals, for patients. And primary measures completion mean the date they unblind - or is that what you were confused about. The latter I could easily believe (in terms of unblinding point), but I realise now I'm not sure about he former.

      Sentiment: Strong Buy

      • 1 Reply to grimboid123
      • Grim, they usually set the date for primary endpoint completion to the time they will be done determining the primary endpoint, not starting the measure of the primary endpoint. If you look at the gem reo panc trial, the primary end point determination (cbr) was just set to December 2013, or about 14 months after the last patient got in study. The trial end date is set to April 2014. As far as I can tell, the end is when no more patients are around.
        So what dose setting the primary endpoint on the head and neck ( which is overall survival) to June 2014 mean? It's hard to say. I presume this can only mean that this is when they will determine the answer ( unblind). The bottom line is it is not clear what the company means by these dates because we can't see the full protocols or the full protocol updates.

    • May 25, 2010: Oncolytics Biotech Inc. Announces Opening of Enrollment in Phase III Trial for REOLYSIN┬« in Head and Neck Cancers (Press Release)

      May 25, 2010 to June 25, 2014 would be 4 years, 1 month

      May 25, 2010 to Sept. 25, 2014 would be 4 years, 4 months


      Sentiment: Strong Buy

      • 1 Reply to xxxscoutxxx
      • With these time lines, if it is a good buy now it will be a roaring good by, oh I mean buy, by then. Also, this should be just in time to do another financing. One positive aspect is that a financing at this time will make it less likely to be shorted but we will pay with a huge dilution. Boy we the small retailer have been a patient lot with this stock over the years true supporters of the science but little else to show for it. Never given any opportunities to participate in any of the financings but seeing a constant erosion of the stock price as a result. I wonder how many more times we have to be kicked before we say enough?

        Sentiment: Hold

0.571-0.039(-6.39%)3:59 PMEDT